

11/29/01

11064 U.S. PTO

12-03-01

A

UTILITY PATENT
APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: VAS-5041CIP2

Page 1 of 2

Title: Drug Eluting Radially Expandable Tubular Stented
Grafts

Express Mail Label No.: EL599141858US

APPLICATION ELEMENTS

INVENTOR(S): Donald T. Shannon

ADDRESS TO: Box Patent Application
Assistant Commissioner for Patents
2900 Crystal Drive
Arlington, VA 22202-35131. ☒ Fee Transmittal Form (Submit an original, and a duplicate
for fee processing)2. ☒ Specification [Total Pages **36**]3. ☒ Claims [Total Pages **38**]4. ☒ Drawing(s) (35 USC §113) [Total Pages **6**]
(Figs.1-9)5. ☒ Signed Declaration [Total Pages **2**]a. ☒ Newly executed (original or copy)b. ☐ Copy from a prior application (37 CFR §1.63(d))

(Note Box 5 below)

i. ☐ DELETION OF INVENTOR(S)Signed statement attached deleting inventor
named in the prior application, see
37 CFR §§1.63(d)(2) and 1.33(b)6. ☐ Incorporation By Reference (useable if Box 4b is checked.)
entire disclosure of the prior application,
from which a copy of the oath or declaration is supplied
under Box 4b, is considered as being part of the
disclosure of the accompanying application and is
hereby incorporated by reference therein7. ☐ Microfiche Computer Program8. ☐ Nucleotide and/or Amino Acid Sequence Submission9. ☐ Assignment Papers with recordation sheet (___pages)10. ☐ 37 CFR §3.73(b) Statement ☐ Power of
Attorney11. ☐ English Translation Document

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.: 09/358,350

19. The present application claims priority under 35 USC § 119 to U.S. Provisional Application No. _____, filed _____.

12. ☒ Information Disclosure
Statement (IDS)/PTO-1449☒ Copies of IDS
Citations13. ☐ Preliminary Amendment14. ☒ Return Receipt Postcard (MPEP 503)15. ☐ Small Entity Statement(s)16. ☐ Certified Copy of Priority Documents (s)17a. ☐ Cancel in the application original claims _____
before calculating the filing fee17b. ☐ Amend the specification by inserting before the first line the
sentence: --This is a ___ Continuation,
___ Divisional, ___ Continuation-in-part, of application
_____, filed _____17c. ☐ I hereby verify that the attached papers are a true copy of the
latest inventor-signed prior application, including a copy of the oath
or declaration showing the original signature or an indication it was
Signed. I hereby verify that the papers are a true copy of the latest
signed prior application number _____, filed _____
and further that all statements made herein of my own knowledge
are true; and further that these statements were made with the
knowledge that willful false statements and the like so made are
punishable by fine or imprisonment, or both, under Section 1001
of Title 18 of the United States Code and that such willful false
statements may jeopardize the validity of the application or any
patent issuing thereon.17d. ☐ Other: _____17e. ☐ Other: _____

11046 U.S. PTO

09/997829



11/29/01

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))


Docket No.: VAS-5041CIP2 Page 2 of 2
Title: Drug Eluting Radially Expandable Tubular Stented
Grafts
Express Mail Label No.: EL599141858US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	102 - 20 =	82	X \$18 =	\$1476
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	2 - 3 =	1	\$84 =	\$84
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 280 =	\$ 0
				BASIC FEE (37 CFR §1.16(a))	\$740
				TOTAL =	\$2300

☒ The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 501225 (Docket VAS5041CIP2).
☒ (For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. ☒ Fees required under 37 CFR §1.16
b. ☒ Fees required under 37 CFR §1.17
c. ☒ Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	Peter J. Gluck, Reg. No. 38,022
SIGNATURE	
DATE	November 28, 2001

CORRESPONDENCE ADDRESS

Edwards Lifesciences LLC
Law Dept.
One Edwards Way
Irvine, California 92614
Telephone: (949) 250-6801 Fax: (949) 250-6850

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above -identified document is being deposited with the United States Postal Service as Express Mail No. EL599141858US in an envelope addressed to Box Patent Application, Assistant Commissioner for Patents, 2900 Crystal Drive, Arlington, VA 22202-3513 on November 28, 2001.

By: 
Jan Lamonica